Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tolbutamide

FDA-approved product (tablet, oral), marketed as Orinase, Tolbutamide, Orinase Diagnostic.

Registered studies
34
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Tolbutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonylureas; Tests for diabetes
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA31.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli20.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae8.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

34registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tolbutamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tolbutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes

    NCT06759922 · start 2025-01-01

    Registered record
    Registry ID
    NCT06759922
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Tab Metformin + Tab Glimepiride; Tab Metformin + Tab Empagliflozin; Tab Metformin +Tab Sitagliptin; Tab Metformin + Tab Empagliflozin + Tab Sitagliptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2025-01-01
    Completion
    2025-06-30
    Enrolment
    172

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionTab Metformin + Tab Glimepiride; Tab Metformin + Tab Empagliflozin; Tab Metformin +Tab Sitagliptin; Tab Metformin + Tab Empagliflozin + Tab Sitagliptin
    PhasePhase 4
    Registry statusCompleted

  • Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

    NCT06449235 · start 2024-09

    Registered record
    Registry ID
    NCT06449235
    Conditions
    Type2diabetes
    Interventions
    Omarigliptin; Sulphonylureas; Metformin; Other DPP4-i; Thiazolidinediones; Alpha-Glucosidase Inhibitor; Glucagon-Like Peptide-1; Receptor Agonists (GLP1RA); SGLT2 inhibitors
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-09
    Completion
    2025-06
    Enrolment
    938

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType2diabetes
    InterventionOmarigliptin; Sulphonylureas; Metformin; Other DPP4-i +5 more
    PhasePhase 4
    Registry statusUnknown

  • A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers

    NCT05830799 · start 2023-03-29

    Registered record
    Registry ID
    NCT05830799
    Conditions
    Drug Interaction
    Interventions
    Drug Drug Interaction
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-03-29
    Completion
    2023-05-11
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Interaction
    InterventionDrug Drug Interaction
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide

    NCT05097716 · start 2021-11-02

    Registered record
    Registry ID
    NCT05097716
    Conditions
    Healthy Volunteers
    Interventions
    Ritlecitinib; Tolbutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-11-02
    Completion
    2022-01-10
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionRitlecitinib; Tolbutamide
    PhasePhase 1
    Registry statusCompleted

  • Phenotyping of High Dose Rifampicin

    NCT04525235 · start 2021-01-07

    Registered record
    Registry ID
    NCT04525235
    Conditions
    Tuberculosis
    Interventions
    phenotyping cocktail; rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-01-07
    Completion
    2021-08-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionphenotyping cocktail; rifampicin
    PhasePhase 1
    Registry statusCompleted

  • BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)

    NCT04044001 · start 2019-11-15

    Registered record
    Registry ID
    NCT04044001
    Conditions
    Pulmonary Tuberculoses; Other Specified Pulmonary Tuberculosis
    Interventions
    BTZ-043; Rifafour e-275®; Probe Drug Cocktail; Dolutegravir 50mg Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-11-15
    Completion
    2022-05-31
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculoses; Other Specified Pulmonary Tuberculosis
    InterventionBTZ-043; Rifafour e-275®; Probe Drug Cocktail; Dolutegravir 50mg Tab
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Licorice Botanical Dietary Supplements - Metabolism and Safety in Women

    NCT03948243 · start 2019-04-01

    Registered record
    Registry ID
    NCT03948243
    Conditions
    Food-drug Interaction
    Interventions
    Licorice; Alprazolam 2 MG; Caffeine 100 MG; Tolbutamide 250 mg; Dextromethorphan 30mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-04-01
    Completion
    2022-04-22
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFood-drug Interaction
    InterventionLicorice; Alprazolam 2 MG; Caffeine 100 MG; Tolbutamide 250 mg +1 more
    PhasePhase 1
    Registry statusCompleted

  • A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

    NCT03723395 · start 2018-09-17

    Registered record
    Registry ID
    NCT03723395
    Conditions
    Drug-drug Interaction
    Interventions
    tucatinib; itraconazole; rifampin; gemfibrozil; repaglinide; tolbutamide; midazolam; digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-09-17
    Completion
    2018-12-28
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-drug Interaction
    Interventiontucatinib; itraconazole; rifampin; gemfibrozil +4 more
    PhasePhase 1
    Registry statusCompleted

  • Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

    NCT03457597 · start 2018-03-06

    Registered record
    Registry ID
    NCT03457597
    Conditions
    Healthy
    Interventions
    Midazolam hydrochloride; Metoprolol tartrate; Pioglitazone hydrochloride; Tolbutamide; Omeprazole; Relacorilant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-03-06
    Completion
    2018-04-28
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMidazolam hydrochloride; Metoprolol tartrate; Pioglitazone hydrochloride; Tolbutamide +2 more
    PhasePhase 1
    Registry statusCompleted

  • Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

    NCT03291288 · start 2018-02-26

    Registered record
    Registry ID
    NCT03291288
    Conditions
    Drug Interaction Potential
    Interventions
    Tolbutamide; Midazolam; Pexidartinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-02-26
    Completion
    2021-04-16
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Interaction Potential
    InterventionTolbutamide; Midazolam; Pexidartinib
    PhasePhase 1
    Registry statusCompleted

  • A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

    NCT03492580 · start 2018-02-22

    Registered record
    Registry ID
    NCT03492580
    Conditions
    Diabetes Mellitus, Type 2; Cardiovascular Diseases
    Interventions
    Canagliflozin; Empagliflozin; Dapagliflozin; Dipeptidyl Peptidase-4 (DPP-4) Inhibitors; Glucagon-like Peptide-1 (GLP-1) Agonist; Anti-hyperglycemic Agents (AHA); Thiazolidinediones (TZD); Sulfonylureas (SU); Insulin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-02-22
    Completion
    2018-06-25
    Enrolment
    714,582

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2; Cardiovascular Diseases
    InterventionCanagliflozin; Empagliflozin; Dapagliflozin; Dipeptidyl Peptidase-4 (DPP-4) Inhibitors +5 more
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers

    NCT03103568 · start 2017-03-28

    Registered record
    Registry ID
    NCT03103568
    Conditions
    Drug Drug Interaction
    Interventions
    Nitisinone in Arm A; Tolbutamide; Metoprolol; Chlorzoxazone; Furosemide; Nitisinone in Arm B
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-03-28
    Completion
    2017-07-24
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Drug Interaction
    InterventionNitisinone in Arm A; Tolbutamide; Metoprolol; Chlorzoxazone +2 more
    PhasePhase 1
    Registry statusCompleted

  • Drug Interaction Study of CT1812 in Healthy Volunteers

    NCT03716427 · start 2016-11-10

    Registered record
    Registry ID
    NCT03716427
    Conditions
    Healthy Volunteers
    Interventions
    CT1812; tolbutamide; dextromethorphan; Omeprazole; midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-11-10
    Completion
    2017-02-15
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionCT1812; tolbutamide; dextromethorphan; Omeprazole +1 more
    PhasePhase 1
    Registry statusCompleted

  • An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates

    NCT02819102 · start 2016-03

    Registered record
    Registry ID
    NCT02819102
    Conditions
    Hereditary Angioedema
    Interventions
    BCX7353 and probes
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-03
    Completion
    2016-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Angioedema
    InterventionBCX7353 and probes
    PhasePhase 1
    Registry statusCompleted

  • Effect of Acute Ethanol Consumption on The Activity of Major Cytochrome P450 Enzymes, NAT2 and P-glycoprotein

    NCT02515526 · start 2015-06

    Registered record
    Registry ID
    NCT02515526
    Conditions
    AOD Effects and Consequences
    Interventions
    caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses; ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-06
    Completion
    2015-08-27
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAOD Effects and Consequences
    Interventioncaffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses; ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses
    PhaseNot applicable
    Registry statusCompleted